This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Gregory Lafyatis | |
|---|---|
| Name | Gregory Lafyatis |
| Birth place | United States |
| Occupation | Rheumatologist, Researcher, Professor |
| Alma mater | Yale University School of Medicine |
| Known for | Systemic sclerosis research, TGF-β studies |
Gregory Lafyatis is an American physician-scientist and rheumatologist noted for his work on systemic sclerosis, fibrosis, and transforming growth factor-beta signaling. He has held academic appointments and clinical leadership roles at major institutions and contributed to translational research linking immunology, dermatology, and pulmonary medicine. Lafyatis's work spans patient care, laboratory investigation, and collaborative clinical trials.
Lafyatis completed undergraduate and medical training in the United States, including an M.D. from Yale University School of Medicine. His postgraduate training included residency and fellowship experiences in internal medicine and rheumatology at prominent centers associated with Johns Hopkins University, Massachusetts General Hospital, and other academic hospitals. Early mentors and collaborators included investigators from National Institutes of Health, Food and Drug Administration, and academic departments at Harvard Medical School and University of Pennsylvania.
Lafyatis has held faculty positions in departments of rheumatology, dermatology, and medicine at major academic centers, collaborating with researchers from Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, and UCLA. He served in roles bridging clinical service and research, interacting with investigators at University of California, San Francisco, University of Michigan, and international groups affiliated with European League Against Rheumatism and American College of Rheumatology. His career includes membership in multidisciplinary consortia involving National Heart, Lung, and Blood Institute and National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Lafyatis's research has focused on systemic sclerosis (scleroderma), pulmonary fibrosis, and cutaneous fibrosis, emphasizing signaling pathways such as Transforming growth factor beta (TGF-β), connective tissue growth factor, and innate immune mediators. He contributed to studies integrating genomics, transcriptomics, and proteomics, collaborating with teams using technologies developed at Broad Institute, Wellcome Sanger Institute, and Stanford University. His work connects to disease models studied at Massachusetts Institute of Technology and cellular signaling frameworks involving members of the Protein kinase and SMAD family signaling networks. Lafyatis participated in multicenter clinical trials coordinated with pharmaceutical partners and clinical research networks including ClinicalTrials.gov registries and groups such as Scleroderma Clinical Trials Consortium.
In clinical practice Lafyatis led multidisciplinary teams managing connective tissue diseases, coordinating care with specialists in pulmonology at centers like Cleveland Clinic and dermatology units at Mayo Clinic. He contributed to guideline development with organizations including American Thoracic Society, European Respiratory Society, and the American College of Rheumatology, and engaged in institutional leadership aligning clinical programs with research initiatives at academic hospitals such as Mount Sinai Hospital and Yale New Haven Hospital. He mentored trainees from programs associated with Columbia University Vagelos College of Physicians and Surgeons and University of Chicago Pritzker School of Medicine.
Lafyatis has received recognition from professional societies including citations and awards from American College of Rheumatology, European League Against Rheumatism, and regional rheumatology associations. His contributions were acknowledged by research funding agencies such as the National Institutes of Health and foundations supporting autoimmune disease research like the Scleroderma Foundation and private philanthropies associated with university endowments. He has been invited to deliver named lectures at meetings of American Thoracic Society, British Society for Rheumatology, and international congresses sponsored by World Health Organization partner organizations.
- Lafyatis contributed to landmark studies on TGF-β signaling and fibrosis published in journals connected to American Journal of Respiratory and Critical Care Medicine, Journal of Clinical Investigation, and Arthritis & Rheumatology. - He co-authored translational research integrating skin transcriptomics and clinical phenotyping appearing in venues associated with Nature Medicine, Science Translational Medicine, and The New England Journal of Medicine. - Additional publications include collaborative reviews and guidelines in Annals of the Rheumatic Diseases, Chest (journal), and consensus statements with societies such as the American Thoracic Society.
Category:American rheumatologists Category:Medical researchers